Merck Just Found a Way to Fix Leaky Blood Vessels in the Eye

In plain English: instead of just stopping the leak, remigromig tells the cells lining your retinal blood vessels to tighten up and repair themselves. It's the difference between putting a bucket under a dripping ceiling and actually fixing the roof.

That distinction matters because it means remigromig attacks DME through a mechanism that no other approved drug touches. If the full data hold up, doctors could have a genuinely new option for patients who don't respond to anti-VEGF therapy, or potentially use it in combination with existing treatments for a one-two punch.

The Road to BRUNELLO

Remigromig didn't appear out of nowhere. Its origin story traces back to EyeBio, a company Merck acquired to build out its ophthalmology ambitions. EyeBio had developed the drug (then called EYE103/Restoret) based on preclinical work showing that synthetic Wnt agonists could restore vascular integrity in the retina.

The AMARONE Phase 1/2 study, which began around mid-2023, tested the drug in treatment-naïve DME patients and in combination with anti-VEGF for neovascular AMD. Those results were promising enough to green-light the pivotal program. BRUNELLO launched as a head-to-head comparison against ranibizumab (Lucentis), one of the most established names in retinal care.

Merck is also running a second pivotal DME study called BAROLO, plus a Phase 2 trial called SUPER TUSCAN in neovascular AMD and retinal vein occlusion. (Yes, Merck's ophthalmology team apparently names everything after Italian wine regions. No complaints here.)

Why Wall Street Is Cautiously Pouring Champagne

Analysts are treating this as a legitimate pipeline win, but they're not ready to spike the football. The bullish case is straightforward: a first-in-class mechanism just cleared a pivotal hurdle in a massive patient population, and it could open a commercial opportunity that some observers have pegged in the multi-billion-dollar range.

The cautious case is equally real. Full efficacy and safety data haven't been released yet; the topline announcement is a highlight reel, not the full game tape. Early signals suggest potentially higher rates of vitreous hemorrhage and discontinuations compared to ranibizumab, which investors will scrutinize closely. And the BAROLO confirmatory study still needs to read out before anyone can call this a done deal.

Broader Merck sentiment is supportive: compiled analyst ratings show roughly 71% buy and 29% hold, though that reflects the whole company, not just this one drug. Remigromig is a credible blockbuster candidate, but it's still in the "prove it" phase.

Merck's Bigger Ophthalmology Bet

Remigromig isn't Merck's only eye drug. The company is building what it calls a two-pronged retina portfolio: remigromig as the non-VEGF option, and MK-8748, an anti-VEGF/Tie2 bispecific, as a potentially best-in-class version of existing therapy. MK-8748 advanced into pivotal development on the back of promising Phase 1/2a results from its own trial, called RIOJA.

The strategy is clear. Merck wants to own both sides of the DME treatment algorithm: the improved version of what already works and an entirely new approach for the patients current drugs leave behind. If both programs deliver, Merck could become a major force in a retinal disease market that's been dominated by Regeneron's Eylea for years.

The Bottom Line

For a disease where treatment hasn't fundamentally changed in over a decade, BRUNELLO's readout is a genuine inflection point. A novel mechanism matched the standard of care in a rigorous head-to-head trial. That validates the Wnt-pathway approach and gives Merck a credible shot at reshaping how doctors treat diabetic eye disease.

Plenty of questions remain: what does the safety profile look like in detail? Will BAROLO confirm these results? Can remigromig ultimately prove superiority, not just non-inferiority, in subgroups or with combination strategies?

But for now, the leaky hose might finally have a real fix. And that's worth paying attention to.